Clinical Trials, Research and Development
January 4, 2023
Via: PMLiVEThe start of the trial triggers a $5m milestone payment from AZ, which licensed AZD3152 from RQ Bio in May last year, and reinforces the financial position of the UK-based biotech to execute its four scientific programmes focused on viral […]
Clinical Trials, Research and Development
November 21, 2022
Via: GENIn a study published in the journal Cell on November 18, a team led by scientists at Weill Cornell Medicine, and the National Institutes of Health (NIH) have isolated an uncommon and ultrapotent antibody that can neutralize the pathogenic zika […]
September 8, 2022
Via: GENA newly developed antibody that increases the activation of TREM2—a receptor on microglia—reduces amyloid burden and alleviates cognitive decline in mice exhibiting Alzheimer’s disease (AD) pathology. These findings indicate that the antibody, Ab18 TVD-Ig/aTfR, may have promise as a treatment […]
August 17, 2022
Via: World Pharma NewsAs SARS-CoV-2 has evolved and mutated, therapeutic antibodies that worked early in the pandemic have become less effective, and newer variants, especially Omicron, have developed ways to evade the antibodies we make in response to vaccines. A new, broadly neutralizing […]
February 22, 2022
Via: Natalie DunnAs the Omicron variant of the virus that caused the current pandemic spreads and mutates, people are left hoping this will be the end of the healthcare crisis. Unlike previous variants, Omicron seems to be more infectious but less severe. […]
February 11, 2022
Via: Drugs.comThe U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the Omicron variant. The emergency use authorization for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults […]
December 13, 2021
Via: Genetic Engineering and Biotechnology NewsThe results of studies by researchers at Yale University have demonstrated how intranasal vaccination can provide broad-based protection against heterologous respiratory viruses in mice, while systemic immunization, which used an injection to elicit body-wide protection, does not. The studies, focused […]
November 30, 2021
Via: FiercePharmaAs the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against the variant. On Tuesday, Regeneron sounded (PDF) a disquieting […]
September 30, 2021
Via: FierceBiotechAcross the first phase of the pandemic, AstraZeneca went from being a good example of how pharma can step up in times of need to a warning that no good deed goes unpunished. Now, AstraZeneca has a shot at putting […]
July 26, 2021
Via: Medical NewsThe development and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern that could potentially evade a vaccine-induced immune response is an ongoing concern, with the alpha (B.1.1.7), beta (B.1.351), gamma (B.1.248), and delta (B.1.614.2) lineages having […]
July 9, 2021
Via: Medical NewsA recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least […]
July 1, 2021
Via: Medical NewsIn a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited […]
June 10, 2021
Via: Medical NewsVaccines are mostly synonymous with needles, an efficient and effective way to provide immunity to myriad infections. As COVID-19 vaccination efforts roll out across the U.S. and the world, some experts believe that a vaccine administered through the nose could […]
May 27, 2021
Via: Drugs.comA third antibody treatment designed to keep high-risk COVID-19 patients from winding up in the hospital was approved for emergency use by the U.S. Food and Drug Administration on Wednesday. Importantly, in lab tests the newly authorized drug, dubbed sotrovimab, […]
May 19, 2021
Via: PharmaphorumIt’s not uncommon for drug developers put a positive spin on lacklustre clinical data, but CytoDyn’s attempts seems to have irritated the US regulator, specifically relating to its use of subgroup analyses to try to indicate a benefit for leronlimab. […]
February 11, 2021
Via: BioSpaceEurofins launches a new CE marked serological assay for the identification and quantification of antibodies to SARS-CoV-2. This ELISA kit can support vaccination campaigns by confirming the success of a vaccination and monitoring the antibody levels over time. Vaccination against […]
February 10, 2021
Via: Genetic Engineering and Biotechnology NewsThe FDA last night granted Emergency Use Authorization (EUA) for a 700 mg dose of bamlanivimab (LY-CoV555) in combination with a 1400 mg dose of a second Lilly antibody candidate, etesevimab (LY-CoV016), for the treatment of mild to moderate COVID-19 […]
Clinical Trials, Research and Development
January 13, 2021
Via: BioSpaceHemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”). As a result […]
Cell and Gene Therapy, Industry
December 14, 2020
Via: enetic Engineering and Biotechnology NewsReceiving the seasonal flu vaccine each year, in addition to seasonal infections, exposes people to a lifetime of building up immune responses to influenza antigens. Yet, it remains unclear whether infection and vaccination induce distinct influenza-specific immunological memory. A team […]
August 24, 2020
Via: Biopharma DiveA weekend that began with President Trump accusing the FDA on Twitter of stalling the progress of treatments for COVID-19 ended with a press conference in which Trump congratulated agency commissioner Stephen Hahn for issuing a new emergency approval. That […]